Page 17 - Pharma Sector

Booster shot as Medicity set to come up in 200 acres area in Chhattisgarh

Under the project, health facilities with about 5,000 bed capacity would be developed via private investment

Aarti Pharma share price down 5% from day high on order to shut Vapi plant

Aarti Pharma share price: The Gujarat Pollution Control Board has ordered Aarti Pharma to deposit a bank guarantee of Rs 2,50,000

Senores Pharma IPO listing jackpot: Shares debut at bumper 52% premium

Senores Pharma shares listed at Rs 593.70 apiece on the BSE, reflecting a premium of 51.84 per cent over the IPO allotment price of Rs 391

The India story: The journey to becoming the 'pharmacy of the world'

Critical tweaks in laws, spirit of enterprise and the pandemic brought about this transition. Tech and innovation will now define the industry's future

Mankind Pharma inks pact with Innovent for immunotherapy drug in India

Mankind Pharma Ltd and Innovent Biologics on Thursday announced a partnership to exclusively license and commercialise innovative immunotherapy drug Sintilimab, used in the treatment of cancer, in the Indian market. This strategic collaboration aims to address the critical challenges in cancer treatment and improve patient access to innovative therapeutic options in the region, the companies said in a joint statement. Marketed as TYVYT (sintilimab injection) in China, Sintilimab is co-developed by Innovent and Eli Lilly. "Sintilimab is not approved in India. Early next year, we will be filing for its regulatory approval in India and complete all mandatory regulatory processes, including the conducting of a phase 3 clinical trial by Mankind Pharma for its successful approval in India once we receive the permission from the regulator to conduct such clinical trials," a Mankind Pharma spokesperson said. Under the agreement with Innovent, Mankind Pharma will have exclusive rights to ..

Healthcare sector in India to reach $320 billion by 2028, says report

India's pharmaceutical sector is targeting $130 billion by 2030 and biotechnology is aiming for $300 billion by the same year: Great Place To Work report

Action likely against AbbVie executive who signed self-declaration

Pharma cos and docs say medical conferences have declined since March after UCPMP was notified

Online pharmacy operating losses to reduce in FY26, predicts CRISIL

For e-pharmacies, this positive trajectory is being driven by a strategic pivot towards high-margin product segments, such as wellness items and medical equipment

CRISIL analysis: Exports, domestic demand to drive pharma sector's growth

Bulk drug exports are expected to see moderate increases, supported by volume growth from new launches, customised synthesis, and rising demand for complex drugs

Senores Pharma IPO sees 13.88 times subscription on day two of bidding

Senores Pharmaceuticals' initial public offering garnered 13.88 times subscription on Monday, the day two of bidding. The Rs 582-crore initial share sale got bids for 11,84,54,740 shares, as against 85,34,681 shares on offer, as per NSE data. The portion for Retail Individual Investors (RIIs) received 38.34 times subscription, while the non-institutional investors segment got subscribed 24.48 times. Qualified Institutional Buyers (QIBs) part received 35 per cent subscription. Senores Pharmaceuticals Ltd on Thursday said it has secured nearly Rs 261 crore from anchor investors. The IPO will conclude on December 24. The IPO has a price range of Rs 372-391 per share. The Ahmedabad-based company's IPO is a combination of fresh issuance of shares worth Rs 500 crore and an Offer-for-Sale (OFS) of up to 21 lakh shares valued Rs 82.11 crore, by promoters and other selling shareholders, at the upper-end of the price band. Proceeds from the fresh issue will be utilised for setting up a ...

Here's why Aurobindo Pharma gained 2% in trade on December 23; details here

Aurobindo Pharma share rose after it announced that CuraTeQ Biologics s.r.o., a step-down subsidiary of company, has obtained marketing authorisation from UK's MHRA for Bevqolva

Healthcare, pharma sectors raise Rs 14,811 crore via IPOs in 2024

Record fundraising surpasses the previous high of Rs 9,370 cr in 2023

Here's why Alembic Pharma was buzzing in trade on December 20, details here

Alembic Pharma share rose after the company announced that it has received final approval from the USFDA for its ANDA Divalproex Sodium Delayed-Release Capsules USP, 125 mg

Abbott India share rises 3% as JPMorgan ups target to Rs 31,500; details

The surge in Abbott India share price followed reports that JPMorgan, a New York-based financial services firm, raised its target price to Rs 31,500, up from Rs 30,000, signaling an upside of 12%

Nomura's upgrade to 'Buy' lifts Dr Reddy's share over 4% in weak market

The northward move in Dr Reddy's share price came after Tokyo, Japan-based brokerage Nomura upgraded the stock to 'Buy' from 'Neutral'

Piramal Pharma up 7% as JM Financial initiates with 'Buy'; 36% upside eyed

The uptick in Piramal Pharma share price came after domestic brokerage JM Financial initiated coverage with 'Buy' for a target price of Rs 340

Respiratory drug sales surge as pollution, monsoon drive higher demand

Sales in the respiratory market reached Rs 1,638 crore in November 2024, up from Rs 1,522 crore recorded in October 2024, amid a surge in pollution-related illnesses last month

Metropolis Healthcare to acquire Core Diagnostics for Rs 247 crore

Diagnostic chain Metropolis Healthcare on Monday said it will acquire Core Diagnostics for Rs 247 crore. The company's board has approved the acquisition of 100 per cent stake in Core Diagnostics from its existing shareholder Core Diagnostics (Mauritius) Pvt Ltd, Metropolis Healthcare said in a regulatory filing. Pursuant to the completion of acquisition, Core Diagnostics will become a wholly owned subsidiary of the company, it added. "This strategic acquisition will enhance Metropolis Healthcare's advanced cancer testing capabilities and strengthen its footprint in northern and eastern India," the diagnostic chain said. By leveraging Core Diagnostics' strong relationships with leading cancer specialists and hospitals in these regions, Metropolis aims to expand its market reach and specialised testing offerings, it added. "With approximately 1.4 million new cancer cases and nearly a million deaths annually in India, there is a critical need for advanced cancer testing nationwide.

No shortage of anti-TB drugs in country, two months' stock available: Govt

Centre to launch 100-day campaign in high-TB burden districts on Saturday

Granules India share tanks 10% after USFDA's 'OAI' tag for Gagillapur Unit

The fall in Granules India share price came after the company announced that United States Food and Drug Administration (USFDA) has classified the inspection of Gagillapur unit as OAI